Non-alcoholic fatty liver disease (NAFLD) is associated with the metabolic syndrome, especially obesity, hyperlipidaemia and diabetes[@b1], and is now the most common liver disease in both adults and children worldwide[@b2]. Regulation of lipid metabolism in the liver is critical to prevent the development of NAFLD, because NAFLD includes a spectrum ranging from simple steatosis to steatohepatitis (non-alcoholic steatohepatitis: NASH), which worsens to cirrhosis and sometimes hepatocellular carcinoma. The prevalence of NAFLD has been estimated as 17--33% in some countries[@b3], and \~10% of patients with NAFLD develop NASH and 8--26% of individuals with NASH progress to cirrhosis[@b4].

Recently, growing evidence from several epidemiological and clinical studies has indicated beneficial health effects of certain fruits and their components against obesity and its related diseases including dyslipidaemia. Citrus fruits, including lemon (*Citrus limon* Burm. f.), contain various polyphenols that have been shown to have several positive health effects, mainly involving glucose and lipid metabolism, in experimental animal models and humans[@b5][@b6][@b7][@b8]. Of all the bioactive molecules of lemon, eriocitrin (eriodictyol 7-rutinoside) is a major flavonoid[@b9] with antioxidant activity[@b10]. Eriocitrin has a suppressive effect on oxidative stress in diabetic rats[@b11] and a lipid-lowering effect in rats on high-fat and high-cholesterol diets[@b12]. However, the mechanism of regulation of hepatic lipid metabolism by eriocitrin has yet to be elucidated.

To investigate the lipid-lowering mechanism of eriocitrin, we administered oral eriocitrin to a zebrafish model of diet-induced obesity (DIO-zebrafish)[@b13]. Zebrafish is a small teleost that can be used for vertebrate models of human diseases[@b14][@b15][@b16][@b17]. The high degree of genetic conservation in zebrafish compared with mammals contributes to its emergence as a model for obtaining insights into fundamental human physiology[@b18]. In DIO-zebrafish, increases of body weight, plasma triglyceride (TG), and liver steatosis are highly consistent with obesity observed in humans and rodent models of DIO[@b13]. The histology of adipose tissue, such as the liver and visceral fat, is also similar[@b19], as is the pathophysiological pathway of visceral fat, to that in human adipose tissues[@b13]. In addition, we have demonstrated the anti-obesity mechanism of tomato[@b20] and green tea extract[@b21] using the DIO-zebrafish. Thus, DIO-zebrafish could be used to validate the mechanism of visceral adiposity and hepatic steatosis.

In this study, we conducted transcriptome analysis of eriocitrin feeding in DIO-zebrafish to investigate the mechanism of the lipid-lowering effect. We demonstrated that eriocitrin activated mitochondrial biogenesis *in vivo* and *in vitro*, which resulted in a protective effect against hepatic steatosis that was induced by DIO.

Results
=======

Eriocitrin prevents diet-induced hyperlipidaemia and hepatic steatosis
----------------------------------------------------------------------

We conducted eriocitrin feeding experiments to analyse their phenotypic effects on DIO-zebrafish for 4 weeks. The body weight of the overfeeding (OF) group was 1.6-fold higher (*P* \< 0.01) than that of the normal feeding (NF) group at week 4 ([Fig. 1a](#f1){ref-type="fig"}). The body length of the OF group was slightly longer than that of the NF group (*P* \< 0.05, [Fig. 1b](#f1){ref-type="fig"}). However, the body mass index (BMI), which was calculated by dividing the body weight (g) by the square of the body length (cm), was increased 1.4-fold in the OF compared with the NF zebrafish (*P* \< 0.01; [Fig. 1c](#f1){ref-type="fig"}). Plasma TG was also increased (*P* \< 0.05) in the OF group ([Fig. 1d](#f1){ref-type="fig"}). We fed eriocitrin-containing gluten granules to the DIO-zebrafish (32 mg/kg/day) for 4 weeks. Zebrafish ate all the eriocitrin-containing gluten granules within 5 min, and there was no appetite suppression during the feeding experiment ([Supplementary Fig. S1](#s1){ref-type="supplementary-material"}). Eriocitrin administration did not result in a significant difference between the body weight and BMI ([Fig. 1a and c](#f1){ref-type="fig"}), but eriocitrin significantly suppressed the increase in plasma TG in DIO-zebrafish (*P* \< 0.05, [Fig. 1d](#f1){ref-type="fig"}). However, the fasting blood glucose did not significantly differ between the eriocitrin-fed group and the others ([Fig. 1e](#f1){ref-type="fig"}). Eriocitrin reduced lipid accumulation (red spots in [Fig. 1f](#f1){ref-type="fig"}) in liver tissues more than overfeeding with vehicle gluten granules, which was consistent with the decrease in plasma TG.

Transcriptome analysis of the liver of eriocitrin-fed DIO-zebrafish
-------------------------------------------------------------------

To reveal the therapeutic mechanism of eriocitrin against hepatic steatosis, we performed DNA microarray experiments on the liver tissues from eriocitrin-fed zebrafish. We compared the genome-wide expression profiles of zebrafish in the NF or OF groups with vehicle and eriocitrin (four groups in total) to identify genes related to improvement of hepatic steatosis. k-means/median clustering analysis defined 10 clusters, and revealed that clusters 7 and 10 were selectively altered in DIO-zebrafish fed with eriocitrin (OF + Erio group). The average expression levels of clusters 7 and 10 were significantly (*P* \< 0.001) increased by eriocitrin feeding in the NF and OF groups. Expression levels were also significantly (*P* \< 0.001) increased in the OF + Erio group compared with the NF + Erio group ([Fig. 2a, 2b](#f2){ref-type="fig"} and [Supplementary Fig. S2](#s1){ref-type="supplementary-material"}). These findings implied that these clusters were involved in the therapeutic mechanism of eriocitrin. In total, 282 probes of these clusters corresponded to 152 human orthologues ([Supplementary Table S1](#s1){ref-type="supplementary-material"}). Analysis of the genes with altered expression by Gene Ontology (GO) category using GOstat[@b22] revealed that 20 of their 150 human orthologues (13.1%) were involved in ATP synthesis and mitochondrial electron transport ([Table 1](#t1){ref-type="table"}). The GO analysis was conducted in the category of biological process, and *P* \< 0.01 was considered to be significant.

We conducted gene set enrichment analysis (GSEA) of DIO-zebrafish fed with gluten and eriocitrin. GSEA is a powerful method that can analyse expression of every functional group of genes[@b23], and it has been used to clarify the mechanisms of various clinical conditions and effects. GSEA showed that expression of 15 gene sets was significantly higher (false discovery rate \< 0.2) in zebrafish fed with eriocitrin ([Supplementary Table S2](#s1){ref-type="supplementary-material"}). GSEA revealed that the gene set "HUMAN_MITODB_6\_2002" was significantly upregulated in DIO-zebrafish fed with an eriocitrin diet ([Fig. 2c](#f2){ref-type="fig"}). HUMAN_MITODB_6\_2002 is activated by peroxisome proliferator activated receptor γ coactivator 1 (PPARGC1)[@b24] and highly correlated with mitochondrial functions. GO analysis and GSEA suggested that eriocitrin ameliorated hepatic steatosis by activating mitochondrial functions and ATP synthesis.

To confirm the results of GSEA analysis, we conducted quantitative (q)RT-PCR analysis of genes related to lipid metabolism and mitochondrial biogenesis, including genes in DNA microarrays ([Table 2](#t2){ref-type="table"}). Eriocitrin feeding significantly upregulated the mRNA level of lipid metabolism genes, *pparab* (zebrafish homologue of human *PPARA*), *acox1* and *acadm* ([Fig. 3a](#f3){ref-type="fig"}). In addition, *ppargc1al* (zebrafish homologue of human *PPARGC1A*, also called *PGC-1α*), a gene involved in fatty acid oxidation, showed a nonsignificant trend towards (*P* = 0.36) increased expression with eriocitrin feeding ([Table 2](#t2){ref-type="table"}). As for mitochondrial genes, an eriocitrin diet significantly upregulated the mRNA levels of *tfam* and *nrf1*, which are mitochondrial biogenesis markers, and *cox4i1* and *atp5j*, which are involved in ATP synthesis ([Fig. 3c](#f3){ref-type="fig"}).

Eriocitrin induces gene expression related to mitochondrial function in HepG2 cells and reduced lipid accumulation
------------------------------------------------------------------------------------------------------------------

To examine whether the alterations in gene expression detected in eriocitrin-fed zebrafish could be extrapolated to human liver, we treated HepG2 human hepatocarcinoma cells with eriocitrin for 48 h. As for the genes involved in lipid metabolism, qRT-PCR showed that eriocitrin increased the mRNA levels of *ACADM* ([Fig. 3b](#f3){ref-type="fig"}) in a dose-dependent manner. Unlike the results with zebrafish, *PPARA* and *ACOX1* were not affected by eriocitrin exposure. As for mitochondrial gene expression, eriocitrin increased *TFAM*, *COX4I1* and *ATP5J* expression in a dose-dependent manner ([Fig. 3d](#f3){ref-type="fig"}), which was similar to the results observed for the zebrafish model ([Fig. 3c](#f3){ref-type="fig"}).

To investigate the ability of eriocitrin to prevent lipid accumulation, the HepG2 cells were incubated in a medium containing palmitate to induce lipid-overloading conditions. Cultured HepG2 cells were treated with eriocitrin (30 μM) for 2 days and then exposed to 400 μM palmitate with or without eriocitrin. The total lipid levels were detected by Oil Red O staining. Co-treatment of HepG2 cells with palmitate and eriocitrin (Pal + Erio) significantly prevented cellular lipid accumulation (*P* \< 0.05; [Fig. 3e and f](#f3){ref-type="fig"}). qRT-PCR analysis of the same genes in lipid-loaded HepG2 cells ([Supplementary Figs. S3 and S4](#s1){ref-type="supplementary-material"}) showed similar gene expression patterns to those that were observed from the DIO-zebrafish ([Fig. 3a and c](#f3){ref-type="fig"}).

Eriocitrin activates mitochondrial biogenesis
---------------------------------------------

From the results of the transcriptome analysis of eriocitrin treatment, we hypothesized that eriocitrin activates mitochondrial biogenesis. Thus, we performed mitochondrial staining using MitoTracker Red CMXRos, which stained the perinuclear region of the mitochondria. After 48 h incubation with 10 μM eriocitrin, the mitochondrial mass of HepG2 was significantly increased compared with that observed with vehicle treatment ([Fig. 4a, b](#f4){ref-type="fig"}). The mitochondrial biogenesis process involves expression of nuclear-encoded proteins that are essential for replication of mtDNA. We measured mtDNA copy numbers by qRT-PCR. To assess mtDNA content per cell, we measured the number of copies of well-conserved single-copy genes. *PK* was used as a marker for nuclear DNA and *CYTB* for mtDNA, as described previously[@b25]. Treatment with eriocitrin for 72 h significantly increased the mtDNA content in a dose-dependent manner, which corresponded to results observed from the image analysis ([Fig. 4c](#f4){ref-type="fig"}). Subsequently, activation of mitochondrial biogenesis resulted in an increase in intracellular ATP production by eriocitrin treatment ([Fig. 4d](#f4){ref-type="fig"}).

To evaluate the effects of eriocitrin on whole animal physiology, we started eriocitrin exposure at 4 dpf zebrafish for 72 h. At 7 dpf, addition of 10 μM eriocitrin to the breeding water also increased the total ATP content of zebrafish ([Fig. 4e](#f4){ref-type="fig"}), which was consistent with the results for HepG2 cells ([Fig. 4d](#f4){ref-type="fig"}).

Discussion
==========

A lot of research has recently been conducted regarding the mechanism of the development of NAFLD, and a strong correlation has been observed between this mechanism and the origin of metabolic syndrome, mainly obesity. However, the genesis of obesity is multifactorial, and there is evidence that reduced energy expenditure, in particular reduced capacity to utilize fat for metabolic fuel, is an important factor, particularly in the weight-reduced state[@b26]. In obese people, therapeutics often target the mitochondria of metabolically active tissues such as skeletal muscle, liver, adipose tissues, and the heart[@b27]. There is also growing evidence that mitochondria have a key role in NAFLD[@b28][@b29]. Our studies demonstrated that eriocitrin suppressed the increase in serum TG and ameliorated hepatic steatosis through activation of mitochondrial biogenesis in DIO-zebrafish.

Eriocitrin is a stronger antioxidant than the other citrus flavonoid compounds and is abundant in lemon and lime[@b30], with safety proven by the lack of developmental toxicity in zebrafish ([Supplementary Figs. S5 and S6](#s1){ref-type="supplementary-material"}). In addition, a rat feeding test revealed that lemon flavonoids containing 33% eriocitrin could be administered at ≤2 g/kg/day for 4 weeks without causing any toxicological phenotypic changes, including body weight, feeding volume, urine, haematological and biochemical parameters, organ weight, and histology (data not shown). There was no phenotypic change at ≤2 g/kg/day. This finding suggests that the lipid-lowering action of eriocitrin might be limited in lipid dysregulation (e.g., hyperlipidaemia). For example, naringin (a flavonoid found in citrus fruits) has been shown to also improve lipid profiles in a high-fat diet-induced model of obesity in rats, but there was no difference in the treatment group upon normal feeding[@b31]. Previous studies have focused on the lipid-lowering effects of eriocitrin on antioxidant defence mechanisms[@b10][@b11] but have provided little information on its effects on mitochondria. In our previous study using high-fat diet mice, crude extracts of the polyphenol fraction from lemon peel also ameliorated the symptoms of the metabolic syndrome, including dyslipidaemia, with expression of *Ppara* and *Acox1* (mitochondrial β-oxidation enzyme) in the liver[@b32]. Eriocitrin also increased *ppara* and other β-oxidation enzyme genes, *acox1* and *acadm*, suggesting that eriocitrin is the main antidyslipidaemic component in lemon polyphenols. Additionally, PPARA agonist ameliorated NAFLD in mice by modulating the genes for enzymes involved in fatty acid metabolism, including *Acox1* and *Acadm*[@b33], which was similar to eriocitrin-induced expression of *PPARA*.

Eriocitrin also increased the expression of genes involved in mitochondrial biogenesis (*NRF1* and *TFAM*) and ATP synthesis (*ATP5J* and *COX4I1*). NRF1 activates the transcription of several nuclear-encoded genes, especially mtDNA, and its liver-specific inactivation leads to hepatic steatosis and neoplasia[@b34], indicating that the therapeutic mechanism of eriocitrin is through *NRF1* induction. PPARGC1A regulates NRF1-dependent transcription[@b35] and increases expression of nuclear and mitochondrion-encoded genes of oxidative metabolism (lipid oxidation, and electron transport complexes) to promote mitochondrial biogenesis[@b36]. In addition, dietary restriction also increases mitochondrial respiration, with gene expression for PPARGC1A, NRF1 and cytochrome C oxidase subunit IV[@b37], which appears to be consistent with our results for eriocitrin. PPARGC1 also has a role in this pathway by activating NRF1 to induce expression of TFAM, which is important to the transcription of mtDNA[@b36][@b38]. Thus, in DIO-zebrafish and HepG2 cells, eriocitrin may also activate or induce PPARGC1, subsequently promote *NRF1* and *TFAM* expression to induce mitochondrial biogenesis and energy expenditure, and finally ameliorate hepatic steatosis. In spite of the eriocitrin-induced activation of mitochondria, we could not detect any antioxidant activity by DNA microarray analysis, except for upregulation of *prdx3*. Although oxidative phosphorylation is a vital part of the ATP production induced by eriocitrin, it also produces reactive oxygen species such as superoxide and hydrogen peroxide. This leads to propagation of free radicals, which damage cells and contribute to inflammatory disease, NASH and, possibly carcinogenesis. We hypothesized that eriocitrin-induced *prdx3* expression could prevent this pathway as an antioxidative mechanism. Oxidative stress coupled with hepatocyte apoptosis is believed to play a pivotal role in the pathogenesis of NAFLD[@b39][@b40]. In addition, emerging data now suggest that hepatocyte apoptosis may be a key component of the "second hit" involved in the progression of simple steatosis to NASH. In this context, several studies reported that antioxidants attenuate oxidative stress and hepatic steatosis; however, we could not detect the antioxidant properties of eriocitrin in the current study.

To predict the site of action of the therapeutic effects of eriocitrin, we conducted Sub-Network Enrichment Analysis (SNEA)[@b41] of our DNA microarray data. SNEA could identify key molecules regulating the expression of the genes involved in lipid metabolism and mitochondrial biogenesis. Although eriocitrin may influence multiple lipid-metabolizing pathways, similar to other polyphenols, we found that two lipid metabolism pathways, retinoid X receptor (RXR) and sterol regulatory element-binding transcription factor 1 (SREBF1) pathways were significantly (*P* \< 0.01) influenced by eriocitrin feeding ([Table 3](#t3){ref-type="table"}, underlined). Eriocitrin suppressed the RXR pathway, which was consistent with its antidyslipidaemic effects. PPARA regulates genes involved in lipid metabolism via heterodimerization with RXR as an obligate partner[@b42][@b43], suggesting interaction between eriocitrin and RXR, especially RXR-α. RXR antagonist HX531 has been reported to ameliorate obesity[@b44][@b45]; therefore, we hypothesize that eriocitrin acts as an RXR antagonist in liver adiposity. In fact, daidzein (a flavonoid found in soybeans) has been shown to suppress RXR-α expression[@b46] and improve lipid metabolism[@b47], which is in accordance with the prediction of RXR enrolment in eriocitrin pathways. Eriocitrin was also predicted to downregulate the SREBF1 pathway ([Table 3](#t3){ref-type="table"}). *Srebf1* is induced by heterodimerization of liver X receptor (LXR) and RXR[@b48], supporting the RXR hypothesis of eriocitrin described above. In addition, resveratrol, a polyphenol present in peanuts and grapes, has been reported to alleviate alcoholic fatty liver by inhibiting *Srebf1* expression via the Forkhead box o1 (Foxo1) signalling pathway[@b49]. *foxo1* was also decreased by eriocitrin in DNA microarray data, implying a similar mechanism for eriocitrin and resveratrol.

In conclusion, our observations using DIO-zebrafish and cultured human cells demonstrate a novel mechanism of powerful lipid-lowering activity of eriocitrin. Steatohepatitis is sometimes caused by hepatic steatosis and decreases the activity of respiratory chain complexes and impairs the ability to synthesize ATP in patients[@b50]. Eriocitrin promotes mitochondrial β-oxidation and biogenesis and ameliorates high-fat-diet-induced hepatic steatosis.

**Methods**
===========

Ethical approval
----------------

This study has been approved by the Ethics Committee of Mie University, and was performed according to Japanese animal welfare regulation 'Act on Welfare and Management of Animals\' (Ministry of Environment of Japan) and complied with international guidelines.

Preparation of eriocitrin
-------------------------

Eriocitrin was prepared from lemon peel using the modified method of Miyake *et al*[@b51]. The lemon peel was extracted using deionized water. The extract was applied to an Amberlite XAD-16 column (Rohm and Haas, Philadelphia, PA, USA). The column was washed with water, and eluted with 40% ethanol. The eluate was concentrated under reduced pressure and crude lemon flavonoids were obtained. Eriocitrin was prepared from crude flavonoids using preparative HPLC (LC-8A; Shimadzu, Kyoto, Japan) using a YMC-Pack ODS column (50 × 250 mm; YMC, Kyoto, Japan). The purity was determined as \>96% using HPLC (LC-10A; Shimadzu).

Feeding zebrafish and experimental design
-----------------------------------------

Adult zebrafish (AB line; Zebrafish International Resource Center, Eugene, OR, USA) were kept at 28°C under a 14 h light:10 h dark cycle, and water conditions of environmental quality were maintained as previously described[@b52]. Zebrafish were assigned into each dietary group for 2 or 4 weeks with five fish per 1.7-L tank. From 3.5 mpf, zebrafish in the OF group were fed three times per day with *Artemia* (60 mg cysts/fish/day; Miyako Kagaku, Tokyo, Japan), and the control group were fed once daily in the morning (\~09:00 h), as described previously[@b13]. Compared with flake foods that have also been used to feed zebrafish[@b52], the amounts of fat and protein in *Artemia* are higher and lower, respectively, whereas the amount of carbohydrate is comparable[@b53]. Zebrafish fed 5 or 60 mg/day freshly hatched *Artemia* consumed about 80% and 50% of the provided *Artemia*, respectively, translating to 20 and 150 cal. Maintenance energy requirement for zebrafish is \<30 cal[@b54], therefore, it seemed reasonable to induce DIO-zebrafish by this overfeeding protocol. For the eriocitrin-feeding experiments, gluten granules (Wako Pure Chemical Industries, Tokyo, Japan) containing 0.8--1.4% eriocitrin were prepared as described previously[@b55]. Zebrafish were fed the eriocitrin-containing granules (2 mg/day) 20 min before *Artemia* feeding in the morning. We confirmed that 20 min was sufficient for eating these granules during the feeding experiment. After the experiments, the fish were sacrificed by an overdose of anaesthetic solution tricaine methanesulfonate (500 mg/L; Sigma--Aldrich, St. Louis, MO, USA) in distilled water.

Measurement of body weight, plasma TG and blood glucose
-------------------------------------------------------

The body weight and length of zebrafish were measured weekly throughout the study as described previously[@b13][@b20]. For the blood chemistry analyses, zebrafish were deprived of food overnight and blood was withdrawn from the dorsal artery by a heparinized glass capillary needle (GD-1; Narishige, Tokyo, Japan) at the indicated times. Blood glucose[@b20] and plasma TG[@b13] were measured as described previously.

Oil Red O staining
------------------

Liver tissues were collected from zebrafish by surgical manipulation under a stereoscopic microscope (MZ16F; Leica Microsystems, Wetzlar, Germany). The livers were fixed in Histo-Fresh (Falma, Tokyo, Japan) and embedded in Tissue-Tek (Sakura Finetek, Tokyo, Japan) and dissected in a cryostat (Microm HM-550; Thermo Fisher Scientific, Waltham, MA, USA). The sections were stained with Oil Red O (Wako Pure Chemical Industries) as described previously[@b20]. Lipid droplets within the cells were stained with Oil Red O dye as described previously[@b56]. After image capture using an Axiovert 200 M microscope (Zeiss, Thornwood, NY, USA), intracellular lipid accumulation was quantified by measurement of OD~520~ using the Victor2 multilabel plate reader (PerkinElmer, Boston, MA, USA).

DNA microarray experiments
--------------------------

Liver tissues were collected from DIO-zebrafish for each experimental condition. Livers were fixed in RNAlater (Applied Biosystems, Foster City, CA, USA) at 4°C for 1 day. The liver tissues were immersed in 1 ml Isogen (NipponGene, Tokyo, Japan) and homogenized using the Mixer Mill MM 300 (Retsch, Haan, Germany) with 5-mm zirconia beads (BioMedicalScience, Tokyo, Japan) for 3 min at 25 Hz. After homogenization, total RNA was extracted according to the protocol for Isogen, in combination with the clean-up protocol of the RNeasy Mini Kit (Qiagen, Hilden, Germany). The DNA microarray experiments were conducted using the Low RNA Input Fluorescent Linear Amplification Kit (Agilent Technologies, Santa Clara, CA, USA) and G2518A Agilent Zebrafish Whole Genome Oligo Microarrays (Agilent Technologies), as previously described[@b20]. The hybridized microarrays were scanned (Agilent G2565BA microarray scanner) and quantified using Feature Extraction software (Agilent Technologies). One-way analysis of variance (ANOVA) was performed to identify differentially expressed probes (*P* \< 0.01). k-means clustering was conducted using MultiExperiment Viewer MeV4, a module of TM4 microarray analysis software[@b57]. The probes were converted to human orthologues using the Life Science Knowledge Bank (World Fusion, Tokyo, Japan). GSEA and SNEA were conducted using Pathway Studio 7 (Ariadne Genomics, Rockville, MD, USA).

Cell culture and treatment
--------------------------

HepG2 human hepatocarcinoma cells were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM; Invitrogen, Carlsbad, CA, USA), supplemented with 100 μg/ml streptomycin sulphate (Sigma--Aldrich), 100 U/ml penicillin G (Sigma--Aldrich) and 10% (v/v) foetal bovine serum (FBS; Invitrogen), and maintained at 37°C in an atmosphere of 5% CO~2~ and 95% air. Sodium palmitate was dissolved in preheated 0.1 N NaOH and diluted in DMEM containing 1.76% (w/v) bovine serum albumin (BSA), to give a final palmitate concentration of 400 μM, as described previously[@b58]. Palmitate was administered after 48 h treatment with eriocitrin.

qRT-PCR of zebrafish and cultured cells
---------------------------------------

For liver tissues of adult zebrafish, total RNA of each sample was purified as described above. For young zebrafish, eight fish were homogenized in RLT buffer using the Mixer Mill 300. Total RNA was purified using the RNeasy Mini Kit (Qiagen), according to the manufacturer\'s protocol. For cultured cells, total RNA was also purified using the RNeasy Mini Kit. First-strand cDNA was prepared with 200 ng total RNA using the Super Script III First-strand System (Life Technologies, Gaithersburg, MD, USA) with random primers (Life Technologies). qRT-PCR was performed with Power SYBR Green Master Mix (Applied Biosystems) in triplicate, according to the manufacturer\'s protocol. The sequences of the primers are shown in [Supplementary Table S3](#s1){ref-type="supplementary-material"}. The oligonucleotides of these primers were synthesized by Life Technologies.

qRT-PCR for measurement of mtDNA
--------------------------------

DNA was extracted using phenol/chloroform precipitation and stored in water at −80°C until analysis[@b59]. Purity and concentration of DNA recovered were determined with a NanoDrop spectrophotometer. Real-time PCR was performed with Power SYBR Green PCR mix (Applied Biosystems) in an ABI 7300 Real Time PCR System (Applied Biosystems). Quantification of mtDNA was accomplished by calculating the ratio of a mitochondrion-encoded gene (*CYTB*) to a nuclear-encoded gene (*PK*), and expressing it as mtDNA copy number per cell.

Measurement of mitochondrial size
---------------------------------

HepG2 cells were seeded at 5 × 10^4^ cells/ml in tissue-culture-treated μ-slide eight-well plates (ibidi, Martinsried, Germany), and incubated for 48 h with or without eriocitrin. The cells were stained with MitoTracker Red CMXRos (Molecular Probes, Eugene, OR, USA) and Hoechst 33342 (Dojindo, Tokyo, Japan) for 15 min. The final concentration of each fluorescent dye was 1 μM for Mitotracker Red and 40 μg/ml for Hoechst 33342. Cells were rinsed with phosphate-buffered saline, and fresh medium was added. Cells were visualized using a fluorescent Zeiss Axiovert 200 M (Carl Zeiss MicroImaging, Thornwood, NY, USA) and analysed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

ATP quantification
------------------

For the zebrafish study, 4 dpf zebrafish were exposed to eriocitrin for 3 days in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.4 mM CaCl~2~ and 0.16 mM MgSO~4~) at 28°C. Zebrafish were transferred to collection microtubes (Qiagen) with 100 μl E3 medium. One hundred microliters of CellTiter-Glo luminescent cell viability assay reagent (Promega, Madison, WI, USA) was added to each tube containing zebrafish. The zebrafish were homogenized quickly using the Mixer Mill 300.

For the cell-based study, HepG2 cells were seeded in 96-well microplates at 2.0 × 10^4^ cells/well in 100 μl growth medium. Cells were incubated at 37°C for 3 days with eriocitrin. Before the ATP assay started, cell numbers in each well were measured using Calcein-AM (Dojindo), according to the manufacturer\'s instructions. After that, the ATP measurements (CellTiter-Glo luminescent cell viability assay) were performed according to the manufacturer\'s instructions. Fluorescence and luminescence were measured by Victor2 fluorescent plate reader (PerkinElmer).

Eriocitrin toxicity in zebrafish
--------------------------------

Zebrafish embryos were exposed to eriocitrin from 6 hpf to 5 dpf. The number of survivors was counted under a MZ16F stereoscopic microscope (Leica Microsystems). One hour before evaluation of locomotor activity, a fish was removed from each experimental unit and placed in a well with 50 μl of E3 medium in a 96-well, clear-bottom plate for acclimatization. The fish were then video-recorded for 15 min. The resulting footage was evaluated to measure the swimming distance using the EthoVision XT system ver8.0 (Noldus Information Technology, Wageningen, The Netherlands) as described previously[@b60].

Statistical analysis
--------------------

All data were represented as mean ± SEM. Differences between the two groups were examined for statistical significance using Student\'s *t* test. For multiple comparisons, we used one-way ANOVA followed by Bonferroni--Dunn multiple comparison. *P* \< 0.05 was considered to denote statistical significance.
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![Assessment of body weight and length, plasma TG, and hepatic steatosis in zebrafish overfed with eriocitrin.\
(a) Average body weight; (b) average body length; and (c) BMI in each group during 4 weeks feeding. Each group contained 10 fish. All values are mean ± SEM. \**P* \< 0.05, \*\**P* \< 0.01 versus vehicle in the NF group. (d) Plasma TG levels in each group. Four weeks\' administration of eriocitrin reduced plasma TG in the OF group. Values are mean ± SEM; *n* = 10, \**P* \< 0.05. (e) Fasting blood glucose in each group. Values are mean ± SEM; *n* = 10. (f) Oil Red O staining of liver sections. Eriocitrin reduced the number of lipid droplets (red) compared with the OF group. Erio: eriocitrin.](srep03708-f1){#f1}

![Analysis of DNA microarray data.\
(a) Clustering analysis of DNA microarrays and (b) the average expression levels of clusters 7 and 10. (c) GSEA plots showed that expression of a mitochondrial gene module[@b24] was more enriched in the OF + Erio group compared with the OF group.](srep03708-f2){#f2}

![qRT-PCR of genes related to lipid metabolism and mitochondrial functions, and eriocitrin reduced lipid accumulation in HepG2 cells.\
To confirm the DNA microarray analyses, qRT-PCR was conducted. Genes related to lipid metabolism in zebrafish (a) and HepG2 cells (b). Genes related to mitochondrial biogenesis and respiratory function in zebrafish (c) and HepG2 cells (d). All values are means ± SEM; *n* = 5, \**P* \< 0.05, \*\**P* \< 0.01. (e) Oil Red O staining of HepG2. (f) Absorbance of Oil Red O during lipid accumulation. Eriocitrin reduced lipid accumulation in palmitate-stimulated HepG2. All values are means ± SEM; *n* = 8, \**P* \< 0.05.](srep03708-f3){#f3}

![Eriocitrin increased mitochondrial biogenesis and ATP production.\
(a) Eriocitrin (10 μM) increased mitochondrial size (red) of HepG2 cells using MitoTracker Red CMXRos staining. Blue colour represents the nucleus (Hoechst 33342). (b) Quantitative analysis of mitochondrial staining. (c) Quantification of mtDNA was accomplished by calculating the ratio of *CYTB* to nuclear *PK* and expressing it as mtDNA copy number per cell. (d), (e) ATP quantification with eriocitrin administration. Upon 72 h administration of eriocitrin, there were increased intracellular ATP in HepG2 cells (d) and systemic ATP of 7 dpf zebrafish (e). All values are mean ± SEM; *n* = 8, \**P* \< 0.05, \*\**P* \< 0.01.](srep03708-f4){#f4}

###### Ontology analysis of genes with altered expression (clusters 7 and 10 in [Fig. 2a](#f2){ref-type="fig"}) in eriocitrin administration

  Group                   GO ID                                 GO Terms                                                                                              genes                                                                     *P* value
  -------------------- ------------ ---------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------
  ATP synthesis         GO:0006119                     Oxidative phosphorylation                      atp5o, ndufs3, atp5d, ndufa4, atp5h, ndufa8, atp5l, ndufa6, atp6v1f, hcg_25371, ndufb5, ndufs6, atp5c1, ndufb6, ndufb2, ndufb8, ndufa2    1.84E-17
                        GO:0042775         Organelle ATP synthesis coupled electron transport                               hcg_25371, ndufb5, ndufs6, ndufs3, ndufb6, ndufa4, ndufa8, ndufb2, ndufa6, ndufb8, ndufa2                           1.30E-12
                        GO:0009145        Purine nucleoside triphosphate biosynthetic process                                               atp5o, atp6v1f, atp5c1, atp5d, atp5j2, atp5h, nme1, atp5l                                           1.10E-06
                        GO:0009108                   Coenzyme biosynthetic process                                                             atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2                                             0.000211878
  Electron transport    GO:0006120        Mitochondrial electron transport, NADH to ubiquinone                                    ndufb5, ndufs6, ndufs3, ndufb6, ndufa4, ndufa8, ndufb2, ndufa6, ndufb8, ndufa2                                1.54E-12
                        GO:0015985   Energy coupled proton transport, down electrochemical gradient                                                atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d                                                  1.39E-05
                        GO:0015992                          Proton transport                                                                   atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2                                              2.07E-05
  Other                 GO:0006752             Group transfer coenzyme metabolic process                                                       atp5o, atp5h, atp6v1f, atp5l, atp5c1, atp5d, atp5j2                                              2.39E-05
                        GO:0006414                      Translational elongation                                                                           rplp0, rplp1, eef1b2, rplp2                                                         0.001341631
                        GO:0051289                    Protein homotetramerization                                                                                 atpif1, pcbd1                                                                0.006574703

###### qRT-PCR and DNA microarray results of eriocitrin administration

                         qRT-PCR                   DNA microarray                              
  ---------- -------- ------------- -------------------------------------------- ------------- ------------------------------------------
  pparab      557714   0.37 ± 0.05    1.18 ± 0.28 [\*](#t2-fn2){ref-type="fn"}        nd                           nd
  acox1       449662   0.64 ± 0.12                  1.24 ± 0.26                   1.04 ± 0.21                 1.02 ± 0.13
  acadm       406283   0.73 ± 0.14    1.20 ± 0.14 [\*](#t2-fn2){ref-type="fn"}    0.98 ± 0.11   1.34 ± 0.13 [\*](#t2-fn2){ref-type="fn"}
  cox4i1      326975   0.59 ± 0.05   1.21 ± 0.13 [\*\*](#t2-fn3){ref-type="fn"}   1.01 ± 0.03   1.43 ± 0.15 [\*](#t2-fn2){ref-type="fn"}
  atp5j       406599   0.72 ± 0.06    1.03 ± 0.12 [\*](#t2-fn2){ref-type="fn"}    1.06 ± 0.10   1.72 ± 0.16 [\*](#t2-fn2){ref-type="fn"}
  ppargc1a    553418   0.27 ± 0.18                  0.46 ± 0.11                       nd                           nd
  nrf1        64604    1.31 ± 0.32    3.43 ± 0.55 [\*](#t2-fn2){ref-type="fn"}    0.94 ± 0.16                 1.04 ± 0.14
  tfam        571106   0.42 ± 0.02    1.01 ± 0.12 [\*](#t2-fn2){ref-type="fn"}    0.78 ± 0.02   1.16 ± 0.10 [\*](#t2-fn2){ref-type="fn"}

All values are mean ± SEM; *n* = 4 or 5,

\**P* \< 0.05,

\*\**P* \< 0.01.

###### Prediction of eriocitrin mechanism using SNEA

  Gene set seed                                    Name                             Total \# of neighbours   \# of measured neighbours                                                                                                                                                                                                                                Measured neighbours                                                                                                                                                                                                                                Median change   *P* value
  --------------------- ---------------------------------------------------------- ------------------------ --------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- -----------
  [RXR]{.ul}                               Retinoid X receptor                               248                        68               APOA4, VEGFA, DDAH1, LCN2, FGFR1, CAV1, SCARB1, ABCC2, CYP27A1, FGB, HMOX1, MGP, ACOX1, CA2, NR1D1, ARG2, CYP8B1, VDR, ABCG5, LPL, CEBPA, PTPN6, RBP1, APOA1, CETP, DBI, FOS, MYOD1, ANGPTL3, THRB, BCL2, EGFR, BCL2L1, NDRG1, SLC2A2, ACADM, SLC27A2, ACLY, ACO1, PTH1R, CYP4A11, FABP1, GATA6, MEIS1, RXRG, COL1A2, PLIN2, SCP2, SLC27A1, CRABP1, CYBB, DUSP1, CCND1, ACACB, TRIB3, CYBA, ANGPTL4, ABCA1, NR1H4, NR1H3, HAND2, LDLR, SLC13A1, MAF, DCN, EGR1, RETN, SLC26A5      −1.017         0.004
  [SREBF1]{.ul}          Sterol regulatory element binding transcription factor 1            134                        50                                                                                SLC2A2, CAV1, PTGDS, CEBPB, ABCA1, FABP1, CETP, ACSS2, HMGCS1, DBI, LPIN1, IRS2, PFKFB1, ACACB, ALDH1A2, INSIG1, VEGFA, PKLR, PDX1, SLC27A2, FDPS, HK2, RETN, ACLY, FADS2, ELOVL5, HMOX1, LPL, AR, HNF4A, LIPE, LIPC, CYP8B1, ACSL1, GNAI2, GPX3, PGD, CASP2, IDH1, HSD17B7, COL6A1, TRIB3, DHCR7, GPAM, SP1, HDC, LDLR, SCARB1, BAX, CEBPA                                                                       −1.055         0.005
  STAT6                     Signal transducer and activator of transcription 6               119                        20                                                                                                                                                                                     CAV1, BCL2, BAX, IGFBP1, COL1A2, BCL2L1, AICDA, AGT, IRS2, SOCS3, MUC5AC, IGF1, CDKN1B, MUC1, CLCA1, EGR1, MAF, PML, VCAM1, NFIL3                                                                                                                                                                            −1.450         0.006
  CDX2                                    Caudal type homeobox 2                              64                        11                                                                                                                                                                                                                  IRS2, HNF1A, CDH17, FABP2, HNF4A, VDR, ACAT2, SP1, HBEGF, LYPLA1, BCL2                                                                                                                                                                                                           1.328         0.007
  MAPK11                           Mitogen-activated protein kinase 11                        36                        11                                                                                                                                                                                                                   SCARB1, BAX, BCL2, HMOX1, VDR, CEBPD, PRDX1, CAV1, CEBPB, EGR1, CCND1                                                                                                                                                                                                           1.025         0.007
  Luteinizing hormone                               \-                                        69                        15                                                                                                                                                                                                   LDLR, SCARB1, EGFR, AREG, CEBPD, RETN, C13orf15, KDR, IGFBP5, ANXA5, FLT1, IGFBP2, SGK1, PSEN1, CEBPB                                                                                                                                                                                          −1.238         0.007
  NKX2-5                                      NK2 homeobox 5                                  52                        14                                                                                                                                                                                                         CALR, TLL1, CTNNB1, GATA4, PITX2, ACTC1, DIO2, MEF2A, ACACB, T, PLOD1, MYOD1, HOPX, ACTA2                                                                                                                                                                                                −1.360         0.008
  HEY1                      Hairy/enhancer-of-split related with YRPW motif 1                 23                        11                                                                                                                                                                                                                    MDM2, RUNX2, ID1, ACTA2, KDR, GATA4, GATA6, MYF5, OCLN, AR, PRODH2                                                                                                                                                                                                            −1.342         0.008
  Runt                              Runt-related transcription factor                         50                         9                                                                                                                                                                                                                       BCL2, C13orf15, LGALS3, CEBPD, TGFBR1, BTG2, SP1, IL7R, RUNX2                                                                                                                                                                                                              −1.368         0.009
